Transcutaneous and intradermal vaccination

Combadière, Béhazine; Liard, Christelle

doi:10.4161/hv.7.8.16274

Cited by 140 publications

(137 citation statements)

References 145 publications

Supporting

Mentioning

129

Contrasting

Unclassified

Order By: Relevance

“…The presence of adjuvant might shape the immunity toward the humoral responses (31). In addition, the route of administration will also impact the immunological outcomes (32,33). In accordance, we also observed increased serum avidity directed against A(H1N1)pdm09 vaccine and increased influenzaspecific neutralizing Abs.…”

Section: Discussionsupporting

confidence: 74%

Longitudinal and Integrative Biomodeling of Effector and Memory Immune Compartments after Inactivated Influenza Vaccination

Bonduelle

Yahia

Sibéril

et al. 2013

The Journal of Immunology

Self Cite

View full text Add to dashboard Cite

Most vaccines, including those against influenza, were developed by focusing solely on humoral response for protection. However, vaccination activates different adaptive compartments that might play a role in protection. We took advantage of the pandemic 2009 A(H1N1) influenza vaccination to conduct a longitudinal integrative multiparametric analysis of seven immune parameters in vaccinated subjects. A global analysis underlined the predominance of induction of humoral and CD4 T cell responses, whereas pandemic 2009 A(H1N1)–specific CD8 responses did not improve after vaccination. A principal component analysis and hierarchical clustering of individuals showed a differential upregulation of influenza vaccine–specific immunity including hemagglutination inhibition titers, IgA+ and IgG+ Ab-secreting cells, effector CD4 or CD8 T cell frequencies at day 21 among individuals, suggesting a fine-tuning of the immune parameters after vaccination. This is related to individual factors including the magnitude and quality of influenza-specific immune responses before vaccination. We propose a graphical delineation of immune determinants that would be essential for a better understanding of vaccine-induced immunity in vaccination strategies.

show abstract

Section: Discussionsupporting

confidence: 74%

Longitudinal and Integrative Biomodeling of Effector and Memory Immune Compartments after Inactivated Influenza Vaccination

Bonduelle

Yahia

Sibéril

et al. 2013

The Journal of Immunology

Self Cite

View full text Add to dashboard Cite

show abstract

“…It is not known whether the distribution of the injected volume in the skin influences the targeting of intradermal injection depths. Furthermore, it is unclear whether local changes in innate immunity can be expected, as antigenbearing DCs will migrate to lymph nodes, where lymph node-residing DCs may influence any immunological effect (14,30). This behavior, chemotaxis and chemoattraction of other DCs and the complex interplay between different DC classes, may explain the absence of differences in immune response as function of the injection depth.…”

Section: Discussionmentioning

confidence: 99%

“…Langerhans cells (LCs) reside in the epidermis (topmost skin layer) and dermal dendritic cells (DDCs) reside in the dermis (lower layer) (14). Both LCs and DDCs have distinct immune functions and may therefore have a different role in immunization (14). Therefore, targeting different skin depths may affect the efficiency of intradermal IPV immunization.…”

Section: Introductionmentioning

confidence: 99%

“…This is of interest, as several classes of dendritic cells (DCs) reside in either the epidermis or the dermis. Langerhans cells (LCs) reside in the epidermis (topmost skin layer) and dermal dendritic cells (DDCs) reside in the dermis (lower layer) (14). Both LCs and DDCs have distinct immune functions and may therefore have a different role in immunization (14).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Determination of Depth-Dependent Intradermal Immunogenicity of Adjuvanted Inactivated Polio Vaccine Delivered by Microinjections via Hollow Microneedles

et al. 2016

View full text Add to dashboard Cite

Purpose The aim of this study was to investigate the depthdependent intradermal immunogenicity of inactivated polio vaccine (IPV) delivered by depth-controlled microinjections via hollow microneedles (HMN) and to investigate antibody response enhancing effects of IPV immunization adjuvanted with CpG oligodeoxynucleotide 1826 (CpG) or cholera toxin (CT). Methods A novel applicator for HMN was designed to permit depth-and volume-controlled microinjections. The applicator was used to immunize rats intradermally with monovalent IPV serotype 1 (IPV1) at injection depths ranging from 50 to 550 μm, or at 400 μm for CpG and CT adjuvanted immunization, which were compared to intramuscular immunization. Results The applicator allowed accurate microinjections into rat skin at predetermined injection depths (50-900 μm), -volumes (1-100 μL) and -rates (up to 60 μL/min) with minimal volume loss (±1-2%). HMN-mediated intradermal immunization resulted in similar IgG and virus-neutralizing antibody titers as conventional intramuscular immunization. No differences in IgG titers were observed as function of injection depth, however IgG titers were significantly increased in the CpG and CT adjuvanted groups (7-fold).Conclusion Intradermal immunogenicity of IPV1 was not affected by injection depth. CpG and CT were potent adjuvants for both intradermal and intramuscular immunization, allowing effective vaccination upon a minimally-invasive single intradermal microinjection by HMN.

show abstract

“…38,39 Current understanding of the cellular response to intradermal vaccination was summarized in a 2011 review by Combadiere and Liard. 40 Following injection into the skin, resident antigenpresenting cells, especially epidermal keratinocytes, Langerhans cells and dermal dendritic cells, capture and are activated by vaccine antigens, leading to their migration through the dermis and eventually to the draining lymph nodes. Recruited innate immune cells in the skin also capture the antigens or are activated via Toll-like receptors and nucleotide-binding domain leucinerich repeat receptors.…”

Section: Intradermal Vaccinationmentioning

confidence: 99%

Intanza^®9 µg intradermal seasonal influenza vaccine for adults 18 to 59 years of age

Leroux-Roels

Weber

2013

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

Transcutaneous and intradermal vaccination

Cited by 140 publications

References 145 publications

Longitudinal and Integrative Biomodeling of Effector and Memory Immune Compartments after Inactivated Influenza Vaccination

Longitudinal and Integrative Biomodeling of Effector and Memory Immune Compartments after Inactivated Influenza Vaccination

Determination of Depth-Dependent Intradermal Immunogenicity of Adjuvanted Inactivated Polio Vaccine Delivered by Microinjections via Hollow Microneedles

Intanza^®9 µg intradermal seasonal influenza vaccine for adults 18 to 59 years of age

Contact Info

Product

Resources

About

Transcutaneous and intradermal vaccination

Cited by 140 publications

References 145 publications

Longitudinal and Integrative Biomodeling of Effector and Memory Immune Compartments after Inactivated Influenza Vaccination

Longitudinal and Integrative Biomodeling of Effector and Memory Immune Compartments after Inactivated Influenza Vaccination

Determination of Depth-Dependent Intradermal Immunogenicity of Adjuvanted Inactivated Polio Vaccine Delivered by Microinjections via Hollow Microneedles

Intanza®9 µg intradermal seasonal influenza vaccine for adults 18 to 59 years of age

Contact Info

Product

Resources

About

Intanza^®9 µg intradermal seasonal influenza vaccine for adults 18 to 59 years of age